TD Cowen analyst Phil Nadeau has maintained their bullish stance on KZR stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Phil Nadeau has given his Buy rating due to a combination of factors related to Kezar Life Sciences’ recent developments and clinical trial results. The company reported positive outcomes from its Phase 2 trial of zetomipzomib in autoimmune hepatitis (AIH), where a significant percentage of patients achieved biochemical remission compared to the placebo group. This demonstrates the potential efficacy of the treatment, which is further supported by the acceptable safety profile observed in the trial.
Additionally, the FDA’s decision to lift the partial clinical hold on the AIH trial and the upcoming Type C meeting to discuss the pivotal trial design are promising steps forward for Kezar. These developments indicate a positive trajectory for the company’s drug pipeline, enhancing investor confidence in its future prospects. As a result, Nadeau’s recommendation reflects the potential for significant advancements and value creation in Kezar’s ongoing and future clinical programs.
According to TipRanks, Nadeau is a 3-star analyst with an average return of 2.7% and a 40.87% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Kura Oncology, Syndax Pharmaceuticals, and Biogen.